Showing 6691-6700 of 9735 results for "".
- Alphaeon Launches PROVOQUE™ Facial Serumhttps://practicaldermatology.com/news/alphaeon-launches-provoque-facial-serum/2458567/Alphaeon Corporation has launched PROVOQUE™ Facial Serum to help address the visible signs of skin aging. PROVOQUE Facial Serum is a stem cell-conditioned media containing growth factors secreted by stem cells.
- Second Skin Gets Second Chancehttps://practicaldermatology.com/news/second-skin-gets-second-chance/2458572/A “second skin” polymer may temporarily protect and tighten skin, and smooth wrinkles. Scientists at MIT, Massachusetts General Hospital, Living Proof, and Olivo Labs developed the material, which could also be used to deliver drugs to help treat skin conditions suc
- ASDS: Skin Cancer Treatments Among Most Frequently Performed Procedures in 2015https://practicaldermatology.com/news/asds-skin-cancer-treatments-among-most-frequently-performed-procedures-in-2015/2458576/Dermatologic surgeons performed nearly 10 million medical and cosmetic procedures in 2015 – up 5 percent since 2014 and 27 percent since 2012, according to the 2015 American Society for Dermatologic Surgery (ASDS) Survey on
- New Case Study Highlights Black Henna Tattoo Riskshttps://practicaldermatology.com/news/new-case-study-highlights-black-henna-tattoo-risks/2458573/Black henna tattoos should be avoided, especially during foreign travel, UK doctors warn in BMJ Case Reports. Researchers from the University of Sheffiel
- Global Derm Market Set to Soar Through 2022https://practicaldermatology.com/news/global-derm-market-set-to-soar-through-2022/2458579/The global dermatology market is set to boom from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%,
- Sienna Biopharmaceuticals Completes $34 Million Series A Financinghttps://practicaldermatology.com/news/sienna-biopharmaceuticals-completes-34-million-series-a-financing/2458586/Sienna Biopharmaceuticals, Inc., a development stage company focused on aesthetics and medical dermatology, completed a $34 million Series A financing led by ARCH Venture Partners. Additional investors included Altitude Life Science Ventures, Partner Fund Management, and Venvest Capital, as well
- Vitiligo and Gray Hair Treatment Breakthrough? Study IDs Mechanism That Controls Skin and Hair Colorhttps://practicaldermatology.com/news/vitiligo-and-gray-hair-treatment-breakthrough-study-ids-mechanism-that-controls-skin-and-hair-color/2458587/A pair of molecular signals controls skin and hair color in mice and humans - and could be targeted by new drugs to treat skin pigment disorders like vitiligo, according to a report out of NYU Langone Medical Center in New York City. Finding ways to activate these pathways could lea
- BioPharmX Reports Full Patient Enrollment in Phase 2a Study of BPX-01https://practicaldermatology.com/news/biopharmx-reports-full-patient-enrollment-in-phase-2a-study-of-bpx-01/2458592/BioPharmX Corporation has completed enrollment for its Phase 2a study of the novel topical minocycline gel BPX-01. The Phase 2a study will assess the safety of BPX-01 in 30 patients randomized to 30 days of treatment with either BPX-01 or a placebo. The endpoints of this study include red
- Study: Viveve® Improves Vaginal Laxityhttps://practicaldermatology.com/news/study-viveve-improves-vaginal-laxity/2458595/The Viveve System improves vaginal laxity when compared with a sham procedure, a new study suggests. Top-line results from the VIveve Treatment of the Vaginal Introitus to EValuate Efficacy (VIVEVE 1) show that the procedure is both safe and effec
- CeraVe® Named Official Skincare Sponsor of LPGA Golf Clinics for Womenhttps://practicaldermatology.com/news/cerave-named-official-skincare-sponsor-of-lpga-golf-clinics-for-women/2458599/CeraVe® skincare products, thave been named Official Skincare Partner of the Ladies Professional Golf Association (LPGA) Golf Clinics for Women, reports Valeant <